Clinical trial · Interventional
Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
Does Androgen Suppression Treatment In Prostate Cancer Reduce Myocardial Blood Flow Reserve?
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Suppression of effects of androgens with male sex hormones, androgen suppression treatment (AST), has been known to reduce deaths and prolong life in advanced prostate cancer. There have, however, been concerns raised in previous studies that androgen suppression may be associated with increased rate of heart attacks, particularly in older men. This study looks at prostate cancer patients in The Ottawa Hospital Cancer Clinic to see if treating these patients with androgen suppression is associated with a decrease in blood flow to the heart muscles by using Positron Emission Tomography (PET) and brachial artery ultrasound.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PET scan and ultrasound | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- MPI nuclear scan
- description
- Nuclear MPI for CAD for prostate cancer subjects undergoing treatment and development of normal comparison.
- interventionNames
- Radiation: PET scan and ultrasound
Primary outcomes (1)
- measure
- myocardial flow reserve
- timeFrame
- 6 - 9 months
- description
- The change in global absolute MFR between baseline and follow up PET studies, at a patient level. MFR is defined as the ratio between regional blood flow with maximum vasodilation and baseline regional blood flow.
Secondary outcomes (1)
- measure
- Regional myocardial perfusion
- timeFrame
- 6 - 9 months
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 40 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: Cancer Population: 1. Diagnosis of prostate cancer 2. Treatment group: Scheduled to start AST, at Ottawa Hospital under the care of Radiation Oncology, Urology or Medical Oncology. Control group: no AST scheduled as a treatment option for prostate cancer. Non-Cancer Control Group 1. Male with low pre-test likelihood of coronary artery disease 2. No previous history of cancer. Exclusion Criteria: 1. Known coronary disease including any of previous revascularization, history of myocardial infarction, coronary disease with \>= 50% stenosis in a major coronary vessel on previous angiography, evidence of previous myocardial infarction on 12-lead electrocardiogram, positive myocardial perfusion scan, previous cardiac PET scan, stress echocardiogram or exercise stress test. 2. Subjects with a Summed Stress Score of \>4 attributed to coronary disease on baseline PET images 3. Patients previously treated with AST 4. Patients with a life expectancy of less than 1 year.
References
Publications (0)
Data not yet available